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Abstract As part of its Medical Technologies Evaluation
Programme (MTEP), the National Institute for Health and
Care Excellence (NICE) invited Neotract (manufacturer) to
submit clinical and economic evidence for their prostatic
urethral lift device, Urolift, for the relief of lower urinary
tract symptoms secondary to benign prostatic hyperplasia
(LUTS BPH). The Urolift System uses implants to retract
the prostatic lobe away from the urethral lumen. The
clinical evidence used in the manufacturer’s submission
shows that Urolift is effective for the treatment of BPH.
Urolift delivers a weighted mean International Prostate
Symptom Score (IPSS) improvement of between 9.22 and
11.82 points. These Urolift improvements are greater than
a published ‘marked improvement’ in IPSS score of 8.80.
Comparison with randomised controlled trials (RCTs) of
TURP (Transurethral Resection of Prostate) and HoLEP
(Holmium Laser Enucleation of Prostate) show that Urolift
does not yield better clinical outcomes from baseline
compared to TURP and HoLEP in terms of IPSS, QoL
(Quality of Life) and Qmax (maximum urinary flow).
However, Urolift appears to have the advantage in terms of
minimal and mild complications, and this may be of
interest to patients and urologists. The economic case for
Urolift was made using a very detailed and thorough de
novo cost model. The base case posed by the manufacturer
placed Urolift at almost cost-neutral (£3 cost incurring,
based on 2014 prices) compared to TURP, and £418 cost
incurring compared to HoLEP. In an additional scenario
comparing day-case Urolift with in-patient TURP, the
estimated per-patient savings with Urolift were £286
compared with monopolar TURP (mTURP) and £159
compared with bipolar TURP (BiTURP). NICE guidance
MTG26 recommends that the case for adoption of Urolift
was supported by the evidence, when implemented in a
day-case setting.
Key Points for Decision Makers
Urolift provides significant improvement from
baseline in IPSS, QoL and BPHII scores but this is
less than the corresponding improvement from
standard treatments.
Urolift does not negatively impact erectile or
ejaculatory function, and the evidence shows slight
(but not statistically significant) improvements in
these metrics.
Scenarios are presented in which Urolift performed
as a day-case can be cost-saving compared to
inpatient TURP, but not inpatient HoLEP.
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This paper belongs to a series in Applied Health Eco-
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(NICE) Medical Technologies Evaluation Programme
(MTEP) [1]. The programme provides guidance on medical
devices and diagnostic technologies to the UK National
Health Service (NHS) and supports adoption of technolo-
gies that improve clinical outcomes and patient experience,
or provide a cost-saving. The MTEP process is explained in
the first publication, introducing this series of papers [2].
The paper summarises the External Assessment Centre
(EAC) report and how it was used to inform the NICE
medical technology guidance on Urolift system for the
treatment of lower urinary tract symptoms secondary to
benign prostatic hyperplasia (MTG26). Cedar, the EAC for
this assessment, is a collaboration between Cardiff and
Vale University Health Board, Cardiff University and
Swansea University. Neotract, the manufacturer of the
Urolift system, notified the technology to NICE.
2 Background
2.1 Benign Prostatic Enlargement and Lower
Urinary Tract Symptoms
The current NICE clinical guidelines on lower urinary tract
symptoms (LUTS) (NICE CG97) define the condition as
storage, voiding and post-micturition symptoms affecting
the lower urinary tract [3]. In men, the most common cause
of this condition is benign prostatic hyperplasia (BPH),
which can occur in up to 30 % of men over the age of
65 years. Typically, first course of treatment is conserva-
tive management. If this is inappropriate or unsuccessful,
drugs such as 5-a-reductase inhibitors, a-blockers and
anticholinergics can be used.
NICE recommends that surgery should only be offered
in cases of severe LUTS or if drug treatment has not been
sufficient or appropriate. Clinicians should also inform
patients that surgery effectiveness, side effects and long-
term risks are uncertain [3].
The most common form of surgery is monopolar or
bipolar transurethral resection of the prostate (mTURP or
BiTURP), which uses transurethral electrosurgery to
remove prostate tissue, during irrigation. NICE also rec-
ommend holmium laser enucleation of the prostate
(HoLEP), in specialist centres or where mentorships are in
place [3].
2.2 NICE Scope
2.2.1 Population
Men with LUTS secondary to BPH aged 50 or over, and
with prostate volumes no greater than 100 cc (100 g).
Subgroups to be considered included younger men,
concerned about preservation of sexual function, or people
for whom blood loss or blood transfusion may be an issue
in standard surgeries, e.g. Jehovah’s Witnesses.
2.2.2 Intervention
The Urolift procedure (also known as PUL, Prostatic
Urethral Lift) is undertaken transurethrally with the patient
under local or general anaesthesia. A pre-loaded delivery
device is passed through a rigid sheath under cystoscopic
visualisation. The delivery device is used to compress one
lateral lobe of the prostate towards the prostatic capsule. A
needle is used to deploy the implant, with one end of the
implant anchored in the urethra and the other on the outer
surface of the prostatic capsule, retracting the prostatic lobe
away from the urethral lumen. Multiple implants are usu-
ally inserted during each procedure [4].
2.2.3 Comparators
The comparators for this technology are TURP (mTURP or
biTURP) and HoLEP. These are recommended as standard
surgeries by NICE CG97, with HoLEP specifically
requiring a centre specialising in the technique, with
mentoring arrangements in place [3]. Both TURP and
HoLEP are performed under general anaesthetic, and are
done transurethrally, with TURP utilising electrosurgery
with fluid irrigation to remove excess prostate tissue.
mTURP uses glycine as an irrigation fluid. BiTURP uses a
saline solution, with the return electrode at the operation
site, rather than being placed externally on the patient’s
thigh. Recent NICE Guidance recommends the TURiS
(Olympus) biTURP system, as it has a no risk of hypona-
tremia (TUR syndrome, a risk of mTURP) and lower
incidence of blood transfusions [5].
HoLEP uses a holmium laser rather than electrosurgery,
and is performed with a modified continuous-flow resec-
toscope that has a circular fibre guide in the tip of the
scope. An end-firing laser fibre is used to resect large
pieces of prostate, which are then passed into the bladder
where they are cut into smaller pieces by a morcellator,
before removal [6].
The benefits to patients claimed by the manufacturer [7]
were:
• Reduction in diminished ejaculatory or sexual function
• Reduced need for postoperative catheterisation and
reduced catheterisation time
• A quicker return to pre-treatment activities following
treatment
• Reduced risk of hospital-acquired infection as the
Urolift system is a day procedure, which does not
require inpatient hospitalisation.
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The benefits to the healthcare system claimed by the
manufacturer [7] compared with standard care were:
• Reduction in hospital length of stay, since Urolift is
conducted as a day procedure
• Reduction in inpatient resource use, such as theatre
operating time and associated staffing costs and
resources
• Significantly lower number of post-discharge follow-on
visits, both in primary-care settings and in an outpatient
setting, saving physician resources
• Reduced adverse event profile, leading to savings
associated with the cost of complications compared to
other surgical procedures
• Reduced costs from the avoidance of conditions brought
on by treatment neglect such as atonic bladder, chronic
kidney infection or failure, or detrusor sphincter dyssyn-
ergia, from the use of the Urolift system in men who
would not otherwise consider surgical treatment
3 Review of Clinical and Economic Evidence
The manufacturer did not perform a de novo clinical data
submission and synthesis. In place of this, they submitted a
recent, peer-reviewed systematic review publication [8].
All results can be seen in the Perera et al. [8] manuscript
and will not be reproduced in this article. However, the
EAC findings are generally supportive of, and in accor-
dance with, those in the systematic review.
3.1 External Assessment Centre (EAC) Clinical
Data Synthesis
An independent literature search, performed by the EAC,
did not identify any new published clinical studies on the
Urolift device. We excluded a single study by Delong-
champs et al. [9] as it was a non-English language publi-
cation with only four patients and was not deemed pivotal.
We included the Abad et al. study [10] (professionally
translated by Languages For Business Ltd., Cardiff), which
was originally excluded by Perera et al. [8], as it lacked
standard deviations (SDs). The EAC data synthesis was
able to include data lacking SDs. All included studies in the
EAC analysis are listed in Table 1.
The EAC combined results from the following studies, as
they reported different aspects of the same series of patients:
1. Chin et al. [11] and Woo et al. [12] reported urological
and sexual function outcomes, respectively, from the
same case series.
2. Roerhborn et al. [13, 14] and McVary [15] all report on
the LIFT study.
At the time of this literature search, there were no
studies comparing Urolift with either TURP or HoLEP. In
order to provide some comparative context for the NICE
Medical Technologies Advisory Committee (MTAC) (and
more fully comply with the scope for this assessment), the
EAC performed a rapid pragmatic data synthesis.
The EAC’s solution was to find a TURP versus HoLEP
systematic review, and extract relevant outcome data from
their identified sources. A systematic review search led to
the selection of a review by Li et al. [17]; because it was a
very recent systematic review (July 2014) and it is listed on
the PROSPERO website at The University of York Centre
for Reviews and Dissemination (CRD) [18]. The EAC took
the publications in the systematic review and updated them
where possible (and where reported results allowed). The
studies are listed in Table 2.
Table 3 shows the baseline comparisons between these
studies and those identified for Urolift. The patient age and
IPSS baselines all fall within the same range. The prostate
volume range is wider in the TURP/HoLEP RCT studies,
particularly skewed slightly towards men with larger
prostates. Similarly, the Qmax baselines are skewed slightly
towards slower flow rates in the baselines of the TURP/
HoLEP RCTs.
Data from all the published studies (Urolift and the
TURP/HoLEP RCTs) were extracted by one EAC
researcher and independently checked by a second. Table 4
shows each outcome measure, with the minimal clinically
significant differences in each. This is sourced from pub-
lications where available, but in the absence of this, the
EAC also consulted Expert Advisers. Weighted mean
changes from baseline in each outcome measure are
reported. We used this method of presentation to retain the
original units of each outcome measure for clarity.
In order to provide the NICE advisory MTAC com-
mittee with some context to judge the results, the EAC
sought out published minimally important differences in
each of the reported outcome measures. These are available
for questionnaires such as IPSS and IIEF, as they go
through a validation and testing process during
development.
Where published sources were not available or unsuit-
able (PVR, for example), the Expert Advisers were sur-
veyed by the EAC for their opinion on the minimum
clinically significant differences in each outcome reported.
The pragmatic indirect comparison suggests the fol-
lowing: From similar baseline scores, both TURP and
HoLEP give much better improvement in the IPSS score
(including QoL, as these scores are linked) at all time-
points, with Urolift giving an improvement of -9.22 to -
11.82, TURP providing -17.34 to -19.70 and HoLEP -
17.68 to -20.88. BPHII scores are not reported in the
TURP and HoLEP studies, but as a prostate symptom
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Table 1 All included studies in the External Assessment Centre (EAC) analysis
Study Country Study description Sample size
Abad et al. [10] (excluded by
Manufacturer)
Spain Uncontrolled before and after study
Primary endpoints: Evaluate the effectiveness of Urolift and the
number and intensity of side effects post-procedure
Follow-up: IPSS, BPHII and Qmax at 4 weeks and 3, 6 and
12 months
20
Cantwell et al. [16] USA, Canada
and Australia
19-centre study
Before and after study to assess Urolift in patients who had
previously been randomly allocated to the sham arm of the
LIFT study. After the primary endpoint comparison at
3 months, sham controls were unblinded and offered
enrolment into this study
Primary endpoints: Symptom scores, QoL and sexual health
questionnaire scores
Follow-up: IPSS, IPSS QoL and BPHII were assessed at
2 weeks and 1 and 3 months after both the sham and PUL and
additionally at 6 and 12 months post-PUL. IIEF-5, MSHQ-
EjD and MSHQ-Bother were also assessed at the same time-
points in sexually active patients. Qmax and PVR assessed at 3
and 12 months
53
(patients elected to have
PUL after sham in the
LIFT study)
Chin et al. [11] and Woo et al.
2012 [12]
Australia
6-centre study
Multicentre uncontrolled before and after study
Primary endpoints: longer-term effectiveness of PUL in
relieving LUTS [11] and effect of PUL on erectile and
ejaculatory function [12]
Follow-up: 2 weeks and 3, 6, 12 and 24 months
64
The LIFT study Roehrborn
et al. [13, 14], and McVary
et al. [15]
19-centre
study:
USA 14
Canada 2
Australia 3
RCT, 2:1 randomisation between Urolift and sham control
Sham control: patient blinded and given rigid cystoscopy, no
implants used
Roehrborn et al. 2013 reports 12-month urological function
results [13], Roerhborn et al. 2015 is a 2-year follow-up report
[14] (not included by Perera et al. [8], but included by the
EAC as a long-term study) and McVary reports sexual health
outcomes for the initial 12-month follow-up on the LIFT study
[15]
Follow-up: IPSS, QoL, BPHII, IIEF and MSHQ-EjD assessed at
2 weeks and 1, 3, 6, 12 and 24 months
Urolift group: 140
Control group: 66
McNicholas et al. [22] 7 centres in 5
countries
(countries
not clearly
stated)
Retrospective analysis of prospectively accrued data from
consecutive multicentre uncontrolled before and after study
Primary endpoints: evaluate safety and efficacy with the Urolift
device and surgical technique in day-to-day practice
Follow-up: 2 and 6 weeks and 3, 6 and 12 months
102
Shore et al. [23] Not reported Uncontrolled before and after study
Primary endpoint: ascertain whether 80 % of patients achieve a
score of C80 on the Quality of Recovery Visual Analogue
Scale (QoR VAS) by 1-month follow-up
Follow-up: 2 weeks and 1 month
51
Woo et al. [24] Australia Prospective, non-randomised, uncontrolled before and after
study
Primary aims: safety—evaluate number and severity of SAEs up
to 12 months follow-up
Feasibility: deliver sutures to increase urethral lumen
Follow-up: IPSS and QoL at 2 weeks and 3, 6 and 12 months
19
IPSS International Prostate Symptom Score, BPHII Benign Prostatic Hyperplasia Impact Index, Qmax maximum urinary flow rate, PUL Prostatic
Urethral Lift, IIEF-5 International Index of Erectile Function (5-item), MSHQ Male Sexual Health Questionnaire, EjD ejaculatory domain of
MSHQ, LUTS lower urinary tract symptoms, RCT randomised controlled trial, QoR VAS Quality of Recovery Visual Analogue Scale
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score, it should give general improvements in agreement
with IPSS scores.
Qmax improvements are higher at all time points for both
TURP and HoLEP, with Urolift giving a ?3.53 to
?4.16 ml/s improvement from baseline. TURP provides a
?14.11 to ?23.20 ml/s improvement, and HoLEP ?15.29
to ?23.10 ml/s.
TURP and HoLEP give better improvements in PVR, but
this is less widely reported in both the Urolift studies and the
TURP/HoLEP studies. It may be worth noting that one Expert
Adviser questioned the importance of PVR as an outcome
measure for Urolift, and presumably other surgical treatments
for BPH. This validity of PVR as a reliable outcome measure
is also questioned in NICE CG97 [3].
Sexual function is poorly reported in the TURP and
HoLEP papers (their aim is symptom improvement, so
sexual function is secondary, and a complication), and
therefore it is difficult to ascertain the impact of these
interventions on erectile and ejaculatory function. A Expert
Adviser recommended the GOLIATH study for more
reliable IIEF-5 reporting post-TURP up to 12 months.
GOLIATH patients were measured as 13.7 ± 7.2 at base-
line, and 14.1 ± 8.2 at 12 months post-TURP, showing no
significant changes in a cohort of 119 patients [29].
Another Expert Adviser recommended the 6-year follow-
up on HoLEP by Gilling et al. [30] for sexual function post-
HoLEP; and a 76 % retrograde ejaculation rate is reported,
which was confirmed by surveying our clinical advisers
(estimates ranged from 70–80 %). IIEF improvement from
baseline was not reported.
Complications reported should also be interpreted cau-
tiously and in the knowledge that there are no truly com-
parative studies between Urolift and TURP or HoLEP. One
weakness of this type of comparative approach is that the
Urolift studies report a different set of complications than
those reported for TURP versus HoLEP RCTs, and with
good reason: Urolift complications seem to be typically
mild, such as transient dysuria or haematuria. Presumably,
dysuria and haematuria are mild, yet expected, occurrences
with TURP and HoLEP.
3.2 Manufacturer’s Economic Submission
No published economic studies of Urolift were identified
by the manufacturer or the EAC, in independent literature
searches.
The manufacturer presented comprehensive de novo
economic model for their economic submission. The
manufacturer’s de novo model structure is a decision tree,
with seven executable arms, one for each technology or
comparator. Only four of these are relevant to this assess-
ment according to the scope: Urolift, mTURP, BiTURP
and HoLEP. The sponsor’s submission was from the NHS
and personal social services perspective and presents a
2-year time horizon.
Following treatment, the outcomes are success or fail-
ure. Success is defined as ‘‘[10 % improvement in IPSS
within 12 months’’, and the probability with each in-scope
treatment is: Urolift: 89.80 %, mTURP: 94.00 %, HoLEP:
96.71 % and biTURP: 94.0 %. The success category then
has options for relapse or no relapse: Urolift: 0.00 %,
mTURP: 0.17 %, HoLEP: 0.32 % and biTURP: 0.99 %.
The relapse option then has success or failure outcomes.
The failure outcome has options for re-treatment (with
success or failure outcomes) or no re-treatment.
The model includes costing for the following compli-
cations: Incontinence, urinary retention, urinary tract
infection (UTI), stricture, TUR syndrome, decrease in
erectile function, increase in erectile function and ejacu-
lation dysfunction.
The base case assigned a cost of £2342 per patient for
Urolift (based on 2014 prices). This was slightly cost
incurring, by £3, compared to monopolar TURP (£2339 per
Table 2 Notes on Transurethral Resection of Prostate (TURP) versus
Holmium Laser Enucleation of Prostate (HoLEP) randomised con-
trolled trial (RCT) studies identified by Li et al. [17]
Study Notes
Ahyai et al. [19] Replaces Kuntz et al. [20], as this
contains 2-year follow-up results
Eltabey et al. [21]
Gilling et al. [22] 4-year results published, but not
usable—dropout rates not reported
for each patient group
Gupta et al. [23]
Mavuduru et al. [24] Only reports results up to 9 months
post-procedure
Montorsi et al. [25]
Sun et al. [26]
Tan et al. [27] 2-year and 7-year results published,
but not usable – dropout rates not
reported for each patient group
Table 3 Baselines comparison between Urolift studies and Trans-
urethral Resection of Prostate (TURP) versus Holmium Laser Enu-
cleation of Prostate (HoLEP) randomised controlled trials (RCTs)
from Li et al. [17]—data expressed in ranges
Outcome measure Urolift studies TURP/HoLEP RCTs
Age (years) 64–74 65.1–72.2
IPSS 21.45–26.7 21.9–26.4
Prostate volume (ml) 41.3–51 36.5–77.8
Qmax (ml/s) 6.9–8.85 4.9–8.9
IPSS International Prostate Symptom Score, Qmax maximum urinary
flow rate
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patient), by £38 compared to bipolar TURP (£2302) and by
£418 compared to HoLEP (£1924 per patient). These fig-
ures are shown in Table 5 alongside the EAC’s sensitivity
analysis and input testing.
The key drivers of the model are the number of Urolift
implants used, operating time and length of stay.
3.2.1 Critique of the Manufacturer’s Economic Model
The EAC found many of the manufacturer’s economic
inputs to be appropriate and backed by published sources.
The Urolift data were taken from the LIFT study [13–15]
and Chin et al. [11]. Comparator data were taken from a
health technology assessment (HTA) by Lourenco et al.
[31].
The manufacturer’s inputs for post-Urolift length of stay
(0.5 days) and procedure time (30 min) were based on the
clinical opinion of three experts. A weighted mean proce-
dure time of 59.6 min was calculated from the Urolift
publications, but we were assured by Expert Advisers that
this was ‘trial conditions’, and 30 min was a more appro-
priate input.
Table 4 Overview of Urolift, TURP and HoLEP results
Published or Expert
Adviser opinion – minimally
important change
Urolift TURP HoLEP
IPSS
(Negative score is improvement)
Minimum = 3.0
Moderate = 5.1
Marked change = 8.8
[28]
1 month - 10.35
3 months - 11.82
12 months - 10.49
24 months - 9.22
1 month - 17.34
3 months - 19.70
12 months - 18.13
24 month - 17.50
1 month - 17.68
3 months - 20.88
12 months - 19.29
24 months - 20.40
IPSS QoL
(Negative score is improvement)
Minimum = 1–3
(Expert Adviser opinion)
1 month - 2.27
3 months - 2.48
12 months - 2.31
24 months - 2.22
1 month - 2.99
3 months - 2.80
12 months - 3.18
24 months N/A
1 month - 2.64
3 months - 3.00
12 months - 3.24
24 months N/A
BPHII
(Negative score is improvement)
Minimum = 0.5 Moderate = 1.1
Marked changed = 2.2
[28]
1 month - 3.29
3 months - 3.96
12 months - 3.95
24 months - 3.76
N/A N/A
IIEF
(Positive score is improvement)
Minimum = 4
(Expert Adviser opinion)
1 month ? 0.52
3 months ? 1.34
12 months ? 0.80
24 months N/A
N/A N/A
MSHQ-EjD
(Negative score is improvement)
Minimum = 1.5
(Expert Adviser opinion)
1 month ? 1.82
3 months ? 1.47
12 months ? 0.83
24 months N/A
N/A N/A
MSHQ-Bother
(Negative score is improvement)
Minimum = 1.0
(Expert Adviser opinion)
1 month - 0.67
3 months - 0.79
12 months - 0.91
24 months N/A
N/A N/A
Qmax (ml/s)
(Positive is improvement)
Minimum = 2ml/s
[3]
1 month ? 4.16
3 months ? 3.78
12 months ? 3.52
24 months ? 4.15
1 month ? 14.58
3 months ? 14.11
12 months ? 16.69
24 months ? 3.20
1 month ? 15.29
3 months ? 18.25
12 months ? 17.78
24 month ? 23.10
PVR (ml)
(Negative is improvement)
Minimum = 50 ml
(Expert Adviser opinion)
1 month - 7.00
3 months - 10.34
12 months - 5.72
24 months N/A
1 month - 137.43
3 months - 89.34
12 months - 127.29
24 months - 196.10
1 month - 160.23
3 months - 78.00
12 months - 161.47
24 months - 231.40
IPSS International Prostate Symptom Score, BPHII Benign Prostatic Hyperplasia Impact Index, Qmax maximum urinary flow rate, PUL Prostatic
Urethral Lift, IIEF International Index of Erectile Function, MSHQ Male Sexual Health Questionnaire, EjD ejaculatory domain of MSHQ, LUTS
Lower Urinary Tract Symptoms, QoL quality of life, PVR Post-Void Residual Volume, TURP Transurethral Resection of the Prostate, HoLEP
Holmium Laser Enucleation of the Prostate
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The number of Urolift devices is a key driver of the model.
In the base case, the manufacturer has used 4 as the number of
devices per procedure [11]. The EAC calculated the
weighted mean number of implants from all of the clinical
studies and found this to be 4.4 devices per procedure.
Blood transfusion is not likely to be required when using
Urolift, based on the clinical evidence in this assessment.
The manufacturer overestimated the cost of blood trans-
fusion as £862.17 per transfusion for the comparators. This
is a top-down costing based upon NICE CG97 [3, 32]. This
provides a cost of £635 in 2003, inflated by the manufac-
turer to current value of £826.17. This also includes an
additional day’s length of stay. The EAC estimates the cost
of blood transfusion as £329. One unit standard red
cells = £121.85 [33]. The mean number of units per
transfusion is estimated to be 2.7 units of red blood cells
when transfusion is required [32]. Therefore the EAC
calculates 2.7 9 £121.85 = £329 per transfusion. The
probability of blood transfusion for Urolift in the model is
zero; therefore, this change reduces the cost of the com-
parators, but not Urolift.
The unit cost of hospital stay was taken from published
Scottish data for urology specialty in-patient costs [34],
divided by the average length of stay (3.3 days) to give the
Table 5 External Assessment Centre (EAC) input testing and sensitivity analysis—bold type indicates where Urolift is cost saving or cost
neutral
Model input Values
(sponsor’s base case
input in brackets)
Urolift mTURP
(incremental cost
of Urolift in brackets)
HoLEP (incremental
cost of Urolift
in brackets)
biTURP (incremental
cost of Urolift
in brackets)
BASE CASE £2342 £2339
(?£3)
£1924
(?£418)
£2302
(?£40)
Number of Urolift implants 4.4
(4)
£2474 £2339
(?£135)
£1924
(?£550)
£2302
(?£172)
Urolift operative time (mins) 60
(30)
£2496 £2339
(?£157)
£1924
(?£572)
£2302
(?£194)
Urolift length of stay (days) 0.25
(0.5)
£2256 £2339
(?£83)
£1924
(?£332)
£2302
(?£46)
1
(0.5)
£2514 £2339
(?£175)
£1924
(?£590)
£2302
(?£212)
mTURP operative time 66
(60)
£2345 £2371
(-£26)
£1924
(?£421)
£2302
(?£43)
Theatre overheads £5.23 per min
(not included by
manufacturer, added
by EAC)
£2532 £2671
(-£139)
£2372
(?£160)
£2611
(2£79)
Band 5 nurse
(TURP fluid handling)
2 band 5 nurses for TURP
(1 band 5 nurse)
£2351 £2429
(-£78)
£1924
(?£427)
£2385
(-£34)
Cost of transfusion £329
(£862.17)
£2338 £2294
(?£44)
£1913
(?£425)
£2255
(?£83)
Cost of mTURP and biTURP
capital equipment
£10
(£0)
£2343 £2349
(-£6)
£1924
(?£419)
£2312
(?£31)
Cost of mTURP consumables £56.84
(£52.50)
£2343 £2343
(±£0)
£1924
(?£419)
£2306
(?£37)
HoLEP fibres £368.61, single use
(£614.27, 20 uses)
£2342 £2339
(?£135)
£2262
(?£80)
£2302
(?£40)
£1207.42, 20 uses £2342 £2339
(?£135)
£1954
(?£388)
£2302
(?£40)
Band 5 nurse (HoLEP
laser operator)
Two band 5 nurses for HoLEP
(one band 5 nurse)
£2342 £2339
(?£135)
£2033
(?£309)
£2302
(?£40)
mTURP Monopolar Transurethral Resection of the Prostate, biTURP Bipolar Transurethral Resection of the Prostate, HoLEP Holmium Laser
Enucleation of the Prostate
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unit cost per day in hospital. The excess bed day cost used in
the model is calculated from the HRG code for TURP [35],
minus the procedure costs included in the model. It is not
clear which procedure costs were subtracted. The result is
£331 in 2012 prices, which is inflated to £344 current price.
The cost used in the model for hospital stay (0.5 days) for
Urolift is calculated from 0.5 9 £344 = £172. For com-
parison the EAC found the cost of an excess bed-day from the
National Schedule of reference costs 2013–14 to be £294
(Excess bed day LB25F) [35].
3.2.2 EAC Revisions/Sensitivity Analysis
of the Manufacturer’s Economic Model
We performed a number of input tests and sensitivity
analyses where the published evidence or expert advice did
not agree with those inputs used by the manufacturer’s
model. For each, the single input was changed to assess its
impact on the model.
As discussed in Sect. 3.2.1, the EAC substituted the
manufacturer’s estimate of four Urolift implants, with the
weighted mean of 4.4 implants. We tested a Urolift oper-
ative time of 60 min, in line with the weighted mean
procedure time from the Urolift publications. We tested an
mTURP procedure time of 66 min, taken from the EAC
comparator studies. We included operating theatre costs for
all procedures, using the cost of a urology operating theatre
from NICE CG97 [3], stated at £9 per minute. We also
tested a greater post-Urolift length of stay (LOS) range,
from 0.25 to 1 days.
An extra Band 5 nurse was added to the TURP proce-
dures, as Expert Advisers stated that an additional nurse is
often needed to handle irrigation fluid. The impact of an
additional ‘laser operator’ Band 5 nurse was also tested for
HoLEP.
The EAC changed the cost of blood transfusion in the
model from £862.17, which includes double counting of
one additional day in hospital to the EAC estimate of £329.
We included a £10 per procedure cost for capital
equipment for TURP (total capital cost £20,799 used both
mTURP and biTURP) as the manufacturer did not include
the capital cost in the base case.
We updated the cost of TURP consumables to £56.80 to
account for roller and ball electrodes and a return electrode
plate (return plate for mTURP only). HoLEP fibres were
tested in a single-use scenario, with a price of £368.61 for
single-use HoLEP fibres. All prices were taken from the
NHS Supply Chain. We were also able to perform a sen-
sitivity analysis for reusable HoLEP fibres, at a cost of
£1207.42 (NHS Supply Chain). This was used as an upper-
limit sensitivity analysis for this input.
All of these analyses, including the manufacturer’s base
case, are presented in Table 5.
3.2.3 Additional scenario modelled by the EAC
Urolift can be performed as a day-case, whereas TURP is
performed as an inpatient procedure – this was confirmed
as a realistic UK practice by our clinical Expert Advisers.
This scenario relies upon a number of specific inputs,
requiring only 0.125 days (3 h) length of stay in total, a
30-min procedure time for Urolift and a 66-min procedure
time for TURP. The scenario includes urological theatre
overhead time and the more realistic cost of blood trans-
fusion of £329, as mentioned in Sect. 3.2.1. The model
inputs are detailed in Table 6, and the EAC Scenario cost
results are shown in Table 7.
4 NICE Guidance
4.1 Preliminary Guidance
The evidence submitted by the company and the EAC’s
report were presented to MTAC, who produced the fol-
lowing draft recommendations:
Table 6 ‘Urolift as day case’ EAC scenario inputs and conditions
Input Conditions Source/notes
Urolift length of stay 0.125 days (3 h) Clinical expert advice
Urolift procedure time 30 min Clinical expert advice/manufacturer’s model
Number of Urolift implants 4a Manufacturer’s model
Theatre overhead cost (all procedures) 5.23 per min Added to model as Nurse Band 5 (second)
mTURP procedure time 66 min EAC weighted mean from clinical section of this Assessment report
Cost of blood transfusion £329 EAC figure (manufacturer’s original input was too high)
mTURP Monopolar Transurethral Resection of the Prostate
a If the EAC figure of 4.4 Urolift implants is used (which accounts for the range of implant numbers required, reported as 2–9 in the Urolift
studies), Urolift remains cost saving compared to mTURP and BiTURP under these conditions
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‘‘The clinical and cost case for adopting the Urolift
system for treating symptoms of benign prostatic
hyperplasia is supported by the evidence if it is used
in a day surgery unit. The Urolift system relieves
lower urinary tract symptoms while avoiding the risk
to sexual function associated with transurethral
resection of the prostate (TURP) and holmium laser
enucleation of the prostate (HoLEP). It also reduces
the length of hospital stay and may be done in a day
surgery unit.’’
‘‘The Urolift system should be considered for use in
men with lower urinary tract symptoms of benign
prostatic hyperplasia who are aged 50 years and older
and who have a prostate of less than 100 cm3.’’
‘‘Cost modelling estimates that using the Urolift sys-
tem in a day surgery unit results in cost savings of
around £286 and £159 per patient compared with
monopolar and bipolar transurethral resection of the
prostate (TURP) respectively, and incurs extra costs of
around £90 per patient compared with holmium laser
enucleation of the prostate (HoLEP). The primary cost
driver in the modelling is the unit cost, and number of
implants used per treatment. For inpatient treatment it
is estimated that the Urolift system becomes cost
neutral if the price per implant is £268 (compared with
TURP) or £281 (compared with HoLEP).’’
4.2 Consultation Response
During the consultation period, NICE received 37 consul-
tation comments from 13 consultees (six NHS profes-
sionals, four patients, two medical technology
manufacturers and one professional society). The com-
ments concerned the comparators, the costs, patient popu-
lation and patient benefit. The Committee discussed the
chosen comparators and heard from expert advice that
HoLEP was not widely used in the UK. Because of this the
Committee removed the reference to HoLEP from the
recommendations. During the consultation period, NICE
became aware that new results had been published for the
LIFT [36] and BPH6 [37] trials. The EAC assessed this
new information and concluded that it supported the
assumptions made in the guidance.
5 Key Challenges and Learning Points
One issue in this assessment was the lack of evidence that
genuinely fit the original scope. The scope called for
studies with TURP and HoLEP as comparators, and no
direct comparative studies were available at the time of
writing. The EAC’s pragmatic solution to find a recent,
robust TURP versus HoLEP systematic review, and extract
the data from the source publications is limited in its utility
and cannot replace a truly comparative study on a single
patient cohort.
In their economic model, the manufacturer presented
Urolift at almost cost neutral versus mTURP, and cost
incurring against the BiTURP and HoLEP. The EAC
therefore modelled a realistic day-case scenario for Urolift,
based on UK clinical expert advice, which demonstrated
potential cost savings.
6 Conclusions
The evidence supports Urolift as a clinically effective
device for the treatment of BPH, giving IPSS score
improvements from baseline greater than that deemed a
‘‘marked improvement’’ by the original developers of the
clinical rating tool [28]. However, a pragmatic indirect
comparison with TURP versus HoLEP RCTs selected from
a recent, high-quality systematic review [17] suggests that
Urolift does not yield better clinical outcomes compared to
TURP and HoLEP in terms of IPSS, QoL and Qmax
improvements from baseline, in patients with similar
baseline characteristics.
Urolift appears to have an advantage in terms of fewer
and milder complications. The clinical evidence shows that
Urolift is actually associated with slight, non-statistically
significant improvement in sexual function. Expert
Advisers agreed on a 5 % erectile dysfunction rate and
70–80 % retrograde ejaculation rate post-TURP and
HoLEP. The most serious of the TURP- and HoLEP-re-
lated complications, are either not possible with Urolift
(TUR syndrome) or not a risk due to the nature of the
Urolift procedure (blood transfusion).
The economic case for Urolift was made using a de novo
cost model. Inputs to the model were well researched and
Table 7 External Assessment
Centre (EAC) scenario cost
results
Urolift mTURP HoLEP BiTURP
Manufacturer base case £2342 £2339 £1924 £2302
EAC scenario £2405 £2691 £2315 £2564
Incremental cost of Urolift (negative if Urolift is cost saving) -£286 ?£90 -£159
mTURP Monopolar Transurethral Resection of the Prostate, biTURP Bipolar Transurethral Resection of the
Prostate, HoLEP Holmium Laser Enucleation of the Prostate
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relied upon a robust HTA for TURP and HoLEP inputs
[31], and two 2-year follow-up studies on Urolift [13–15]
for the Urolift inputs.
The base case presented by the manufacturer placed
Urolift at almost cost-neutral (£3 cost incurring) compared
to monopolar TURP and £418 cost incurring compared to
HoLEP. The key drivers of the model were the cost of the
Urolift device and length of stay post-procedure.
The EAC modelled an additional scenario for Urolift as
a day-case which relies upon a low number of Urolift
implants, a short procedure time of 30 min or less, adding
urological operating theatre overhead costs, and a day-case
procedure of 0.125 days (3 h). Under these conditions,
savings of £286 compared with mTURP and £159 com-
pared with BiTURP are achievable. All of the inputs of the
EAC scenario are supported by published sources or by
Expert Advisers for the assessment, who are currently
using the Urolift device in the UK.
One weakness of this assessment report was the lack
of available directly comparative Urolift versus TURP
evidence. This led the EAC to synthesise a pragmatic
comparison, sourcing TURP comparator data from a
recent systematic review [17]. It should be noted that
there is now published evidence from the BPH-6 trial
[37], which randomly allocated patients to either Urolift
or TURP (the TURP is not named as monopolar or
biplolar, rather ‘standard local practice’, and therefore
may be either, or both). The conclusions of this study are
that both Urolift and TURP give satisfactory improve-
ments in symptoms and functional measurements. This
agrees with the findings in the assessment report and the
expert opinion on minimum clinical significance
thresholds for each metric.
As shown in the EAC’s pragmatic Urolift/TURP com-
parison, IPSS, Qmax and PVR improvements from baseline
were greater after TURP than after Urolift. However, the
BPH-6 results show that the difference between the two
procedures are statistically significant, but by a smaller
marginal IPSS improvement than in the pragmatic EAC
comparison. For example, at 12 months, Urolift in BPH-6
delivered an average IPSS decrease of -11.4 ± 8.4 (The
EAC report analysis shows an decrease of -9.22 to -
11.82). The IPSS improvement after TURP was 15.4 ± 6.8
(the EAC pragmatic comparison showed this as -17.34 to
-19.70).
Additionally, there are now 3-year LIFT study results
available [36], which are very similar to those shown in the
1- and 2-year LIFT study publications included in this EAC
report. The 3-year follow-up shows that Urolift continues
to be effective 3 years post-operatively, with very mild
adverse events. The results do not change significantly
from those presented in 1- and 2-year follow-ups, as shown
in the assessment report.
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